Baseball Fan Hitting 30 Parks in 30 Days For LLS Fundraiser
Eric Mueller, a baseball fan from Michigan, is undertaking the journey of a lifetime by visiting 30 Major League Baseball stadiums in 30 days to raise money for the Leukemia & Lymphoma Society.
Honoring a father
Mueller, who turns 50 soon, is conducting his "30 Parks in 30 Days to Help Find a Cure" in honor of his father, who died of lymphoma in 2000.
Mueller told Fox News Phoenix:
It's really amazing how many people are touched by blood cancer. It seems like everybody knows a relative or a friend suffering from this and as a result they all want to help. I'm really grateful for all the generous donations … It gets kind of crazy. I'm hopping from Minnesota to Florida, Chicago, Canada for the Blue Jays. I love ballparks. San Francisco was nice, San Diego was nice, Texas was nice. I just enjoy all of them.
His fundraising goal is $25,000.
Check out Mueller's progress at www.30parks30days.com.
Photo of Dodgers Stadium by John Nyboer
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
